We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.62 | -1.64% | 97.44 | 98.22 | 97.44 | 97.76 | 1,562,845 | 01:00:00 |
From Apr 2019 to Apr 2024
By Nathan Allen
Novartis AG's (NOVN.EB) Sandoz subsidiary said Friday it has presented positive data from two phase 3 studies of its Zessly and Erelzi biosimilars.
Results from the two studies show the drugs, which are used to treat rheumatoid arthritis, matched their reference medicine in terms of safety, efficacy and quality, Novartis said.
The research suggests that switching from the reference medicine to either of the biosimilars has no negative effects on safety or efficacy and doesn't damage the patient's ability to generate an immune response, Novartis said.
The European Union approved Zessly for use in Europe in May, while Erelzi received approval last June.
Write to Nathan Allen at nathan.allen@dowjones.com
(END) Dow Jones Newswires
June 15, 2018 01:57 ET (05:57 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
